The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Prevention of Variceal Rebleeding According to the Dose of Propranolol

Propranonol의 용량에 따른 식도 정맥류 재출혈 예방

  • Jang, Jae Young (Institution for Digestive Research, Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Lee, Woong Cheul (Institution for Digestive Research, Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University College of Medicine)
  • 장재영 (순천향대학교 의과대학 내과학교실, 소화기병센터, 소화기연구소) ;
  • 이웅철 (순천향대학교 의과대학 내과학교실, 소화기병센터, 소화기연구소)
  • Published : 2014.01.01
⟨ Previous Next ⟩

Abstract

Esophageal variceal bleeding is a common complication of liver cirrhosis. Non-selective beta blockers (NSBB) have been established in numerous studies as one of the medical treatment for cirrhosis, especially in the primary and secondary prevention of variceal bleeding. The dose of NSBB is adjusted for a reduction in the resting heart rate by 25%, to 55 beat/min, or until the occurrence of adverse effect. The mean adjusted dose of propranolol in Korean study is 160 mg/day. Nevertheless, low dose propranolol is frequently used in real clinical field. A study by Kwon et al. showed that effect of propranolol in the prevention for esophageal rebleeding was superior in maximally-tolerable dose group of propranolol than low dose group. In this editorial, we have reviewed the studies of prevention for variceal rebleeding focusing on the dose of propranolol.

Keywords

References

  1. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332-354.
  2. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med 1988;319:983-989. https://doi.org/10.1056/NEJM198810133191505
  3. Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet 2003;361:952-954. https://doi.org/10.1016/S0140-6736(03)12778-X
  4. Chalasani N, Kahi C, Francois F, et al. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol 2003;98:653-659. https://doi.org/10.1111/j.1572-0241.2003.07294.x
  5. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475-505. https://doi.org/10.1055/s-2007-1007133
  6. Garcia-Pagan JC, Escorsell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Semin Liver Dis 1999;19:427-438. https://doi.org/10.1055/s-2007-1007130
  7. Bosch J, Pizcueta P, Feu F, Fernandez M, Garcia-Pagan JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am 1992;21:1-14.
  8. Kroeger RJ, Groszmann RJ. The effect of the combination of nitroglycerin and propranolol on splanchnic and systemic hemodynamics in a portal hypertensive rat model. Hepatology 1985;5:425-430. https://doi.org/10.1002/hep.1840050314
  9. Suk KT, Kim MY, Park DH, et al. Effect of propranolol on portal pressure and systemic hemodynamics in patients with liver cirrhosis and portal hypertension: a prospective study. Gut Liver 2007;1:159-164. https://doi.org/10.5009/gnl.2007.1.2.159
  10. Kwon HY, Ha KH, Kim SY, et al. Maximally-tolerable versus low dose of propranolol in the prevention of seophageal variceal rebleeding. Korean J Med 2014;86:42-48. https://doi.org/10.3904/kjm.2014.86.1.42
  11. Suk KT, Baik SK, Yoon JH, et al. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol 2012;18:1-21. https://doi.org/10.3350/kjhep.2012.18.1.1
  12. Thiele M, Krag A, Rohde U, Gluud LL. Meta-analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices. Aliment Pharmacol Ther 2012;35:1155-1165. https://doi.org/10.1111/j.1365-2036.2012.05074.x
  13. Mellinger JL, Volk ML. Multidisciplinary management of patients with cirrhosis: a need for care coordination. Clin Gastroenterol Hepatol 2013;11:217-223. https://doi.org/10.1016/j.cgh.2012.10.040
  14. Garcia-Tsao G, Lim JK; Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009;104:1802-1829. https://doi.org/10.1038/ajg.2009.191
  15. Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol 2013 Sep 26 [Epub]. http://dx.doi.org/10.1016/j.jhep.2013.09.016.
  16. Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of ${\beta}$-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012;61:967-969. https://doi.org/10.1136/gutjnl-2011-301348